369 related articles for article (PubMed ID: 24102184)
1. Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.
Baczko I; Liknes D; Yang W; Hamming KC; Searle G; Jaeger K; Husti Z; Juhasz V; Klausz G; Pap R; Saghy L; Varro A; Dolinsky V; Wang S; Rauniyar V; Hall D; Dyck JR; Light PE
Br J Pharmacol; 2014 Jan; 171(1):92-106. PubMed ID: 24102184
[TBL] [Abstract][Full Text] [Related]
2. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.
Burashnikov A; Barajas-Martinez H; Hu D; Robinson VM; Grunnet M; Antzelevitch C
J Cardiovasc Pharmacol; 2020 Aug; 76(2):164-172. PubMed ID: 32453071
[TBL] [Abstract][Full Text] [Related]
3. Exenatide reduces atrial fibrillation susceptibility by inhibiting hKv1.5 and hNav1.5 channels.
Zhou Q; Hao G; Xie W; Chen B; Lu W; Wang G; Zhong R; Chen J; Ye J; Shen J; Cao P
J Biol Chem; 2024 May; 300(5):107294. PubMed ID: 38636665
[TBL] [Abstract][Full Text] [Related]
4. Piceatannol, a derivative of resveratrol, moderately slows I(Na) inactivation and exerts antiarrhythmic action in ischaemia-reperfused rat hearts.
Chen WP; Hung LM; Hsueh CH; Lai LP; Su MJ
Br J Pharmacol; 2009 Jun; 157(3):381-91. PubMed ID: 19371352
[TBL] [Abstract][Full Text] [Related]
5. 18β-Glycyrrhetinic acid preferentially blocks late Na current generated by ΔKPQ Nav1.5 channels.
Du YM; Xia CK; Zhao N; Dong Q; Lei M; Xia JH
Acta Pharmacol Sin; 2012 Jun; 33(6):752-60. PubMed ID: 22609834
[TBL] [Abstract][Full Text] [Related]
6. Ion Channel and Structural Remodeling in Obesity-Mediated Atrial Fibrillation.
McCauley MD; Hong L; Sridhar A; Menon A; Perike S; Zhang M; da Silva IB; Yan J; Bonini MG; Ai X; Rehman J; Darbar D
Circ Arrhythm Electrophysiol; 2020 Aug; 13(8):e008296. PubMed ID: 32654503
[TBL] [Abstract][Full Text] [Related]
7. Effects of the natural flavone trimethylapigenin on cardiac potassium currents.
Liu Y; Xu XH; Liu Z; Du XL; Chen KH; Xin X; Jin ZD; Shen JZ; Hu Y; Li GR; Jin MW
Biochem Pharmacol; 2012 Aug; 84(4):498-506. PubMed ID: 22583923
[TBL] [Abstract][Full Text] [Related]
8. Azithromycin Causes a Novel Proarrhythmic Syndrome.
Yang Z; Prinsen JK; Bersell KR; Shen W; Yermalitskaya L; Sidorova T; Luis PB; Hall L; Zhang W; Du L; Milne G; Tucker P; George AL; Campbell CM; Pickett RA; Shaffer CM; Chopra N; Yang T; Knollmann BC; Roden DM; Murray KT
Circ Arrhythm Electrophysiol; 2017 Apr; 10(4):. PubMed ID: 28408648
[TBL] [Abstract][Full Text] [Related]
9. Theoretical possibilities for the development of novel antiarrhythmic drugs.
Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of potassium currents is involved in antiarrhythmic effect of moderate ethanol on atrial fibrillation.
Yang B; Li C; Sun J; Wang X; Liu X; Yang C; Chen L; Zhou J; Hu H
Toxicol Appl Pharmacol; 2017 May; 322():89-96. PubMed ID: 28284858
[TBL] [Abstract][Full Text] [Related]
12. Eleutheroside B, a selective late sodium current inhibitor, suppresses atrial fibrillation induced by sea anemone toxin II in rabbit hearts.
Zhang PP; Guo ZF; Zhang PH; Liu ZP; Song L; Zhang ZF; Jia YZ; Cao ZZ; Ma JH
Acta Pharmacol Sin; 2021 Feb; 42(2):209-217. PubMed ID: 32612277
[TBL] [Abstract][Full Text] [Related]
13. Role of small-conductance calcium-activated potassium channels in atrial electrophysiology and fibrillation in the dog.
Qi XY; Diness JG; Brundel BJ; Zhou XB; Naud P; Wu CT; Huang H; Harada M; Aflaki M; Dobrev D; Grunnet M; Nattel S
Circulation; 2014 Jan; 129(4):430-40. PubMed ID: 24190961
[TBL] [Abstract][Full Text] [Related]
14. Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes.
Polina I; Jansen HJ; Li T; Moghtadaei M; Bohne LJ; Liu Y; Krishnaswamy P; Egom EE; Belke DD; Rafferty SA; Ezeani M; Gillis AM; Rose RA
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):7990-8000. PubMed ID: 32198206
[TBL] [Abstract][Full Text] [Related]
15. Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.
Ford J; Milnes J; Wettwer E; Christ T; Rogers M; Sutton K; Madge D; Virag L; Jost N; Horvath Z; Matschke K; Varro A; Ravens U
J Cardiovasc Pharmacol; 2013 May; 61(5):408-15. PubMed ID: 23364608
[TBL] [Abstract][Full Text] [Related]
16. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Regan CP; Kiss L; Stump GL; McIntyre CJ; Beshore DC; Liverton NJ; Dinsmore CJ; Lynch JJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):322-30. PubMed ID: 17967939
[TBL] [Abstract][Full Text] [Related]
17. Change in late sodium current of atrial myocytes in spontaneously hypertensive rats with allocryptopine treatment.
Dong Y; Huang Y; Wu HL; Ke J; Yin YL; Zhu C; Li B; Li J; Gao L; Xue Q; Zhang JC; Li Y
Cardiovasc J Afr; 2019 Mar/Apr 23; 30(2):79-86. PubMed ID: 30882133
[TBL] [Abstract][Full Text] [Related]
18. Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide.
Hashimoto N; Yamashita T; Tsuruzoe N
J Cardiovasc Pharmacol; 2008 Feb; 51(2):162-9. PubMed ID: 18287884
[TBL] [Abstract][Full Text] [Related]
19. The calmodulin inhibitor N-(6-aminohexyl)-5-chloro-1-naphthalene sulphonamide directly blocks human ether à-go-go-related gene potassium channels stably expressed in human embryonic kidney 293 cells.
Zhang XH; Jin MW; Sun HY; Zhang S; Li GR
Br J Pharmacol; 2010 Oct; 161(4):872-84. PubMed ID: 20860665
[TBL] [Abstract][Full Text] [Related]
20. In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillation-induced electrical remodeling.
Tsujimae K; Murakami S; Kurachi Y
Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H793-800. PubMed ID: 18055524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
